Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds

Executive Summary

Regeneron Pharmaceuticals Inc. executives emphasized the blockbuster potential of product candidates in the company's late-stage research and development pipeline on Aug. 4, while noting that the top-selling biologic Eylea (aflibercept) is facing increased reimbursement and competitive pressures.

Advertisement

Related Content

Amgen Plugs Away On Repatha, With Hope For New Monthly Product
Is Bayer Making A Mistake With Monsanto When Pharma Is Its Leading Business?
'Transformative' Dupilumab Set For Third Quarter Filing In Atopic Dermatitis
PhRMA Condemns Medicare B Rx Drug Payment Experiment
Protocol T: Little Difference In Eylea, Lucentis Efficacy At Two Years
JPM Parting Shots: Immuno-Oncology Plans For Regeneron, Incyte, Molecular Partners
10 Potential Drug Approvals To Look Out For In 2016
FDA OK's Regeneron's Eylea in diabetic retinopathy
Eylea bests Lucentis in DME, but Avastin wins on cost
FDA approval comes early for Regeneron's Eylea in DME

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097064

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel